ArticleJournal of inflammation (London, England)2025
Associations of leucocyte subtypes and platelet parameters with kidney cancer risk in the UK Biobank cohort.
Article in Journal of inflammation (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKidney cancer is related to obesity and inflammation and platelets are involved in thrombo-inflammation, but the prospective associations of individual leucocyte subtypes and platelet parameters with kidney cancer risk are unclear.
methodsUsing data from the UK Biobank cohort and multivariable Cox proportional hazards models, we obtained hazard ratios (HR per one standard deviation increase) with 95% confidence intervals (95%CI) for the mutually adjusted associations of inflammatory markers and platelet parameters (log-transformed), and allometric obesity indices (body mass index (BMI), a body shape index (ABSI), hip index) with kidney cancer risk (overall, by sex, and by follow-up time with a cut-off at 6 years).
resultsDuring a mean follow-up of 10.4 years, 1086 kidney cancers were ascertained in 396,482 participants. Conditional on each other and covariates, neutrophil count (HR = 1.12; 95%CI = 1.04 - 1.20), C-reactive protein (HR = 1.11; 95%CI = 1.04 - 1.19), platelet count (HR = 1.18; 95%CI = 1.10 - 1.27), platelet distribution width (HR = 1.16; 95%CI = 1.09 - 1.24), and BMI (HR = 1.22; 95%CI = 1.14 - 1.30) were positively associated, while lymphocyte count (HR = 0.90; 95%CI = 0.84 - 0.96) and hip index (HR = 0.88; 95%CI = 0.83 - 0.93) were inversely associated with kidney cancer risk in participants overall, but there was little evidence for an association with ABSI (HR = 1.05; 95%CI = 0.99 - 1.12). There were no major sex differences, but the positive association with C-reactive protein was observed only for shorter follow-up time (HR = 1.26; 95%CI = 1.14 - 1.38; p-follow-up = 0.0006).
conclusionsOur findings support two separate longer-acting pathways in kidney cancer development- a pathway related to general rather than abdominal obesity and an immune-cell-related pathway involving neutrophils assisted by activated platelets, as well as a cancer-induced thrombo-inflammation closer to kidney cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.